Article
DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance.
Blood - 14 Sept 2023
Zhou Nan, Choi Jaewoo, Grothusen Grant, Kim Bang-Jin, Ren Diqiu, Cao Zhendong, Liu Yiman, Li Qinglan, Inamdar Arati, Beer Thomas, Tang Hsin-Yao, Perkey Eric, Maillard Ivan, Bonasio Roberto, Shi Junwei, Ruella Marco, Wan Liling, Busino Luca
Abstract excerpt
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Up to 40% of patients with DLBCL display refractory disease or relapse after standard chemotherapy treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), leading to significant morbidity and mortality. The molecular mechanisms of chemoresistance in DLBCL remain incompletely understood....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.